SCHEMBL21392826

SCHEMBL21392826

C=CC(=O)NCc1ccc(C(=O)Nc2ccc(OCc3cn4ccccc4n3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.56
▸ TDP1 Q9NUW8 5/20 0.54
▸ L3MBTL1 Q9Y468 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.52
▸ HPGD P15428 3/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ TP53 P04637 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ MAPT P10636 3/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ LMNA P02545 2/20 0.50
▸ PDE10A Q9Y233 1/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ MEN1 O00255 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488101 0.74 KDM4E (1.00) KDM4ETDP1L3MBTL1ALDH1A1HPGD
SCHEMBL23488102 0.73 KDM4E (0.80) KDM4ETDP1L3MBTL1ALDH1A1HPGD
SCHEMBL17694678 0.68 KDM4E (0.78) KDM4ETDP1L3MBTL1ALDH1A1HPGD
SCHEMBL244257 0.68 KDM4E (0.56) KDM4ETDP1L3MBTL1ALDH1A1HPGD
SCHEMBL1695687 0.67 KDM4E (0.66) KDM4ETDP1L3MBTL1ALDH1A1HPGD
SCHEMBL1695688 0.67 KDM4E (0.66) KDM4ETDP1L3MBTL1ALDH1A1HPGD
SCHEMBL21392882 0.67 RAB9A (0.55) HPGDCYP2C19CYP1A2SMN1; SMN2LMNA
SCHEMBL6157401 0.67 KDM4E (0.61) KDM4ETDP1L3MBTL1ALDH1A1HPGD
SCHEMBL6157404 0.67 KDM4E (0.61) KDM4ETDP1L3MBTL1ALDH1A1HPGD
SCHEMBL6157407 0.67 KDM4E (0.61) KDM4ETDP1L3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666661-B2 Methods and compounds for targeted autophagy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-06 — — US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 — — US disclosed
WO-2019183600-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-09-26 — — WO disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 KDM4E 3016/4885TDP1 2216/4885L3MBTL1 625/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 KDM4E 210/4885TDP1 1403/4885L3MBTL1 421/4885
US-11666661-B2 Methods and compounds for targeted autophagy ATG7, BECN1, SQSTM1 KDM4E 3016/4885TDP1 2216/4885L3MBTL1 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback